Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs
NDA is supported by Allarity’s previously-filed pre-market approval (PMA) submission to the FDA for the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Kidney Cancer | Marketing | New Drug Applications | Renal Cell Carcinoma